Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Sep 1.

Published in final edited form as: J Cardiovasc Pharmacol. 2021 Sep 1;78(3):411–421. doi: 10.1097/FJC.0000000000001082

Figure 4. — EGB761 attenuates warfarin-induced aortic valve calcification in mice. (A) Representative images of calcium deposits in aortic valve leaflet (von kossa) in mice of different groups (x40 magnification). (B) The percentage of aortic valve area occupied by calcium deposits in the mice treated with warfarin as compared to different dosage of EGB761. n=14 per group. ^*P<0.05 vs. NC group; ^#P<0.05 vs. warfarin group. NC, negative control.

Figure 4. — EGB761 attenuates warfarin-induced aortic valve calcification in mice. (A) Representative images of calcium deposits in aortic valve leaflet (von kossa) in mice of different groups (x40 magnification). (B) The percentage of aortic valve area occupied by calcium deposits in the mice treated with warfarin as compared to different dosage of EGB761. n=14 per group. ^*P<0.05 vs. NC group; ^#P<0.05 vs. warfarin group. NC, negative control.